The conversations on this week’s podcast focus on a rapid and accurate prostate cancer diagnostic test, with Valley Diagnostics’ CEO Dave Taylor; and on gene therapy for retinal disease, with Lance Baldo, CEO of Beacon Therapeutics.

Times:

03:12 Beacon Therapeutics

27:38 Valley Diagnostics

Valley Diagnostics

Valley Diagnostics is a Welsh company developing next‑generation lateral flow diagnostic tests designed for early detection of human and animal diseases.

Their approach uses patented biomarkers to make faster and more accurate screening possible in GP surgeries, point‑of‑care settings, and at home. Their current pipeline includes tests for prostate cancer, lung cancer, and bovine tuberculosis. ...